Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology

M.H.A. Jansen; D.G. van Vuurden; W.P. Vandertop; G.J.L. Kaspers

doi:https://doi.org/10.1016/j.ctrv.2011.06.007

Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology

M.H.A. Jansen, D.G. van Vuurden, W.P. Vandertop, G.J.L. Kaspers

Research output: Contribution to journal › Article › Academic › peer-review

177 Citations (Scopus)

Abstract

Patients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG constitute only 10-15% of all pediatric brain tumors, they are the main cause of death in this group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5 years (including several targeted agents), there is no clear improvement in prognosis. However, knowledge on DIPG biology is increasing, mainly due to the (re)introduction of biopsies and autopsies, the possibility of gene expression profiling, and the development of in vivo models. Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease. (C) 2011 Elsevier Ltd. All rights reserved

Original language	Undefined/Unknown
Pages (from-to)	27-35
Journal	Cancer Treatment Reviews
Volume	38
Issue number	1
DOIs	https://doi.org/10.1016/j.ctrv.2011.06.007
Publication status	Published - 2012

Access to Document

https://doi.org/10.1016/j.ctrv.2011.06.007

Cite this

@article{e94b09a9d8734ba4ab9f07506f6fd483,

title = "Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology",

abstract = "Patients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG constitute only 10-15% of all pediatric brain tumors, they are the main cause of death in this group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5 years (including several targeted agents), there is no clear improvement in prognosis. However, knowledge on DIPG biology is increasing, mainly due to the (re)introduction of biopsies and autopsies, the possibility of gene expression profiling, and the development of in vivo models. Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease. (C) 2011 Elsevier Ltd. All rights reserved",

author = "M.H.A. Jansen and {van Vuurden}, D.G. and W.P. Vandertop and G.J.L. Kaspers",

year = "2012",

doi = "https://doi.org/10.1016/j.ctrv.2011.06.007",

language = "Undefined/Unknown",

volume = "38",

pages = "27--35",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology

AU - Jansen, M.H.A.

AU - van Vuurden, D.G.

AU - Vandertop, W.P.

AU - Kaspers, G.J.L.

PY - 2012

Y1 - 2012

N2 - Patients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG constitute only 10-15% of all pediatric brain tumors, they are the main cause of death in this group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5 years (including several targeted agents), there is no clear improvement in prognosis. However, knowledge on DIPG biology is increasing, mainly due to the (re)introduction of biopsies and autopsies, the possibility of gene expression profiling, and the development of in vivo models. Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease. (C) 2011 Elsevier Ltd. All rights reserved

AB - Patients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG constitute only 10-15% of all pediatric brain tumors, they are the main cause of death in this group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5 years (including several targeted agents), there is no clear improvement in prognosis. However, knowledge on DIPG biology is increasing, mainly due to the (re)introduction of biopsies and autopsies, the possibility of gene expression profiling, and the development of in vivo models. Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease. (C) 2011 Elsevier Ltd. All rights reserved

U2 - https://doi.org/10.1016/j.ctrv.2011.06.007

DO - https://doi.org/10.1016/j.ctrv.2011.06.007

M3 - Article

C2 - 21764221

SN - 0305-7372

VL - 38

SP - 27

EP - 35

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

IS - 1

ER -